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a b s t r a c t
The validation of a microbiological assay applying the cylinder–plate method to determine the quinolone
gemiﬂoxacin mesylate (GFM) content is described. Using a strain of Staphylococcus epidermidis ATCC
12228 as the test organism, the GFM content in tablets at concentrations ranging from 0.5 to 4.5gmL−1
could be determined. A standard curve was obtained by plotting three values derived from the diameters
of the growth inhibition zone. A prospective validation showed that the method developed is linear
(r=0.9966), precise (repeatability and intermediate precision), accurate (100.63%), speciﬁc and robust.
GFMsolutions (from thedrugproduct) exposed todirectUVA radiation (352nm), alkalinehydrolysis, acid
hydrolysis, thermal stress, hydrogen peroxide causing oxidation, and a synthetic impurity were used to
evaluate the speciﬁcity of thebioassay. Thebioassay and thepreviously validatedhighperformance liquid
chromatographic (HPLC) method were compared using Student’s t test, which indicated that there wastaphylococcus epidermidis
n vitro cytotoxicity assay
no statistically signiﬁcant difference between these two validated methods. These studies demonstrate
the validity of the proposed bioassay, which allows reliable quantiﬁcation of GFM in tablets and can be
used as a useful alternative methodology for GFM analysis in stability studies and routine quality control.
The GFM reference standard (RS), photodegraded GFM RS, and synthetic impurity samples were also
studied in order to determine the preliminary in vitro cytotoxicity to peripheral blood mononuclear cells.
The results indicated that the GFM RS and photodegraded GFM RS were potentially more cytotoxic than
der tthe synthetic impurity un
. Introduction
Fluoroquinolone gemiﬂoxacin mesylate (GFM, Fig. 1a) is a syn-
hetic, broad-spectrum antibacterial agent. It is unique in its dual
argeting capacity – achieving adequate plasma concentrations to
nhibit both topoisomerase IV and gyrase – distinguishing it from
therﬂuoroquinolones,which inhibit onebutnotboth targets.GFM
as excellent in vitro activity against bothGram-positive andGram-
egative organisms, including potent antibacterial activity against
espiratory tract infection pathogens, particularly Streptococcus
neumoniae, Haemophilus inﬂuenzae, and Moraxella catarrhalis. It
lso has excellent activity against atypical organisms, such as
egionella pneumophila, Mycoplasma pneumoniae, and Chlamydia
neumoniae [1–3].
∗ Corresponding author. Tel.: +55 51 33085214; fax: +55 51 33085378.
E-mail address: csoldatelli30@hotmail.com (C.S. Paim).
039-9140/$ – see front matter. Crown Copyright © 2010 Published by Elsevier B.V. All ri
oi:10.1016/j.talanta.2010.11.069he conditions of analysis applied.
Crown Copyright © 2010 Published by Elsevier B.V. All rights reserved.
The literature has reported microbiological assays to determine
ﬂuoroquinolones inpharmaceutical formulations, suchasoﬂoxacin
[4], sparﬂoxacin [5], gatiﬂoxacin [6], moxiﬂoxacin [7], enroﬂoxacin
[8], as well as studies describing the determination of GFM in bio-
logical ﬂuids by HPLC–MS [9,10], HPLC–ESI–MS/MS [11] and in
tablets by spectrophotometry [12,13]. However, a microbiological
assay to determine GFM in tablets has not been reported yet.More-
over, it allows the potency of GFM to be assessed, which is very
important for the analysis of antibiotics. The development of alter-
native analytical methodologies, such as a simple, operationally
inexpensive microbiological assay using agar diffusion for antibi-
otics, represents a great advantage for quality control laboratories
not equippedwith specialized, sophisticated instruments [14]. Fur-
thermore, the bioassays’ low cost, simple procedures allowed them
tobecomeanalternativemethodology fordrugpotencyassessment
in pharmaceutical formulations.
The aim of this study was to develop and validate a simple,
speciﬁc, accurate and reproducible microbiological assay by agar
diffusion using the cylinder–plate method to quantify GFM in
ghts reserved.
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uFig. 1. Chemical structures of GFM (a) and its synthetic impurity: 1-cycloprop
ablets as an alternative to the physicochemicalmethods described
n the literature. Moreover, a high performance liquid chromato-
raphic (HPLC) method, developed and validated in our laboratory,
as chosen as a comparisonmethod to determineGFM indegraded
amples.
GFMRS, photodegradedGFMRSand synthetic impurity samples
ere also evaluated to determine the preliminary in vitro cytotox-
city when exposed to mononuclear cells. In agreement with ICH
15], it is important to evaluate the biological safety of an indi-
idual impurity or a given impurity proﬁle, including degradation
roducts.
. Materials and methods
.1. Chemicals
GFMRS (99.0%)was acquired fromToronto Research Chemicals,
nc. (Ontario, Canada). The synthetic impurity, 1-cyclopropyl-6-
uoro-7-chloride-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
arboxylic acid (Fig. 1b), was acquired from AK Scientiﬁc Inc.
Mountain View, CA, United States). Factive® (Aché, Brazil) coated
ablets containing 320mg of gemiﬂoxacin were purchased from
he local market. The excipient ingredients contained in the dosage
orm (microcrystalline cellulose, crospovidone, titanium dioxide,
agnesium stearate, hydroxypropyl methylcellulose, polyethy-
ene glycol, and povidone) were all of pharmaceutical grade and
cquired from different suppliers. All chemicals used were of ana-
ytical grade and all solvents were of HPLC grade. Methanol was
urchased from Tedia (Fairﬁeld, USA). Sodium chloride, sodium
ydroxide, dibasic potassium phosphate, monobasic potassium
hosphate and medium number 1 [16,17] were obtained from
erck (Darmstadt, Germany). RPMI 1640 medium and Hank’s
alanced salt solution were purchased from Sigma® (Missouri,
SA). Puriﬁed water was obtained using a Milli-Q Plus® (Millipore,
edford, USA).
.2. Apparatus
Photodegradation studies were carried out in a photostability
V chamber (1.0m×0.17m×0.17m) with mirrors in its interior
quipped with a UVA lamp (Light Express®, 352nm, 30W), and UV
uvettes (Ultra Vette®, São Paulo, Brazil) were employed as con-
ainers for the samples. For thermal stability studies, a dry air oven
Biomatic®, Porto Alegre, Brazil) was used. An electronic caliper
Mitutoyo®, Tokyo, Japan) was utilized to measure the diameters
n the zone of growth inhibition (mm).
An Agilent® liquid chromatograph (Santa Clara, CA, United
tates) equipped with a model Q 1311A quaternary pump,
LS-G1329A auto sampler, TCC-G1316A column oven, G1315B
hotodiode-array detector and ChemStation manager system soft-
are was used to control the equipment, to calculate data and to
nalyze the responses from theHPLC system. The chromatographic
eparation was performed on an Agilent Eclipse® XDB RP-18 col-
mn (150mm×4.6mm i.d., 5m, Santa Clara, CA, United States).uoro-7-chloride-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (b).
For the cytotoxic assay, a Ficoll-Paque® gradient cen-
trifuge (Amersham Pharmacia Biotech, Uppsala, Sweden) and a
FACSCalibur® cytometer equippedwith488nmargon laser (Becton
Dickinson, San Diego, CA, USA) were used.
2.3. GFM RS solutions
An accurately weighed amount of GFM RS equivalent to 10.0mg
of gemiﬂoxacin base was transferred to a 100mL volumetric ﬂask
and dissolved in methanol to obtain a ﬁnal concentration of
100.0gmL−1. Aliquots of this solutionwerediluted inbuffernum-
ber 1, pH 6.0 [16,17], to achieve concentrations of 0.5, 1.5, and
4.5gmL−1 (S1, S2, andS3, respectively). These solutionswerekept
protected from light.
2.4. Preparation of the sample solution
To prepare the sample solution, 20 Factive® coated tablets were
weighed and ﬁnely powdered. A quantity equivalent to 10.0mg of
gemiﬂoxacin base was transferred into a 100mL volumetric ﬂask
with 60mL methanol, kept in ultrasonic bath for 30min, and the
volumewas completedwith the samediluent. Aliquots of this solu-
tion were diluted in buffer number 1, pH 6.0 [16,17], to achieve
concentrations of 0.5, 1.5, and 4.5gmL−1 (T1, T2, and T3, respec-
tively), which were used in the bioassay. These solutions were kept
protected from light.
2.5. Microorganism and inoculum standardization
The strain of Staphylococcus epidermidis ATCC 12228 obtained
from INCQS (Rio de Janeiro, Brazil) was cultivated after reconsti-
tution and maintained in medium number 1. The microorganism
standardizationwaspreparedaccording to theproceduredescribed
in the Brazilian Pharmacopoeia [16] and USP 32 [17] for microbi-
ological assays with antibiotics. Prior to use, the microorganisms
were transferred and inoculated in a test tube containing the
same medium, which was maintained in a dry air oven for 24h
at 37±2 ◦C. The growth was suspended in 0.9% NaCl sterile solu-
tion. Using a spectrophotometer (Analyser®, São Paulo, Brazil) set
at 580nm and a 10mm absorption cell, the solution containing the
microorganisms was diluted to achieve a suspension turbidity of
25±2% (transmittance) using a0.9%NaCl sterile solution as a blank.
From this inoculated saline solution, 2.0mL portionswere added to
each 100mL of medium number 1, kept in water bath at 48 ◦C and
employed as the inoculated layer in the plate.
2.6. Agar diffusion bioassay
Thebioassaydescribedhere followed the3×3parallel lineassay
design (three doses of the standard and three doses of the sam-
ple in each plate), with eight plates for each assay, according to
the Brazilian and European Pharmacopoeias [16,18]. The base layer
agarwas composed by 20mL ofmediumnumber 1 thatwas poured
into a 100mm×20mmPetri dish. After that layer solidiﬁed, 5.0mL
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ortions of the inoculated medium 1 were poured onto the base
ayer. In each plate, 6 stainless steel cylinders of the same size
8mm×6mm×10mm) were placed on the surface of the inocu-
atedmedium. Three alternated cylinderswereﬁlledwith 200L of
he reference solutions (S1, S2, and S3), and the other three cylin-
ers were ﬁlled with the sample solutions (T1, T2, and T3). The
lates were incubated at 35±1 ◦C aerobically for 18h. The diame-
ers (mm) of the growth inhibition zone were carefully measured
ith an electronic caliper (Mitutoyo®). All experiments were per-
ormed in a biological safety cabinet and the infected material was
econtaminated before being discarded.
.7. Calculations
TheGFMpotencywas statistically calculated by theparallel-line
odel for the 3×3 assay design. An analysis of variance (ANOVA)
as used for the statistical validation of the bioassays, evaluating
he regression, parallelism and linearity of each assay [16,19].
.8. Validation of the method
The methodology was validated according to the USP 32 [17]
nd the International Conference on Harmonization (ICH) [20] by
etermining the following operational characteristics: linearity,
recision, accuracy, speciﬁcity, robustness, stability of the refer-
nce standard and sample solutions.
.8.1. Linearity
Three doses of the reference substance were used in nine inde-
endent assays. Linearity was evaluated by linear regression and
eviation analysis, which were calculated by the least-squares
ethod.
.8.2. Precision
The precision of the method was determined by repeatabil-
ty and intermediate precision and was expressed as the relative
tandard deviation (RSD). Repeatability was examined by assaying
hree GFM samples on the same day (intraday) and under the same
xperimental conditions, and intermediate precision was evalu-
ted by analysis on 3 days (interday).
.8.3. Accuracy
Accuracywasdeterminedby recoveringknownamountsofGFM
S added to the sample solutions. An accurately weighed amount
f tablets equivalent to 10.0mg of gemiﬂoxacin base was trans-
erred to a 100mL volumetric ﬂask and dissolved in methanol
100.0gmL−1). 1.0, 3.0 and 4.5mL aliquots of this solution were
ransferred into volumetric ﬂasks containing 1.0, 3.0 and 4.5mL
f GFM RS (10.0gmL−1). Buffer number 1 pH 6.0 was added to
chieve concentrations of 0.55, 1.65 and 4.95gmL−1 that cor-
espond to 110.0% of the nominal concentrations (as described
n Section 2.4). The cylinders were ﬁlled up with the solutions
escribed above and recovery rates of the added GFM RS were
alculated.
.8.4. Speciﬁcity
The ability of the proposed method to determine GFM in the
resence of degradation products was assessed by comparing the
esults obtained from the degraded samples analyzed by bioassay
nd by the HPLC method (developed and validated in the previous
tudies). Under all conditions, the sample solutions were assayed
nd compared to freshly prepared GFM RS solutions at the same
heoretical concentrations. Speciﬁcity was also checked using the
ynthetic impurity 1-cyclopropyl-6-ﬂuoro-7-chloride-4-oxo-1,4-
ihydro-1,8-naphthyridine-3-carboxylic acid (CAS 100361-18-0)
nd the excipients of the formulation to determine whether these (2011) 1774–1779
substances could interfere with the assay. The preparations of the
stressedGFM, excipients and synthetic impurity solutionswere the
following.
2.8.4.1. Acid hydrolysis. Sample solutionswerepreparedandmain-
tained in 0.1M HCl for 1h and stored at room temperature. After
that, aliquots of these solutions (100.0gmL−1) were removed,
neutralizedwith 0.1MNaOH and diluted in buffer number 1 pH 6.0
to achieve theoretical concentrations of 0.5, 1.5 and 4.5gmL−1.
2.8.4.2. Basic hydrolysis. Sample solutions were prepared and
maintained in 0.01M NaOH for 3h and stored at room tempera-
ture. After that, aliquots of these solutions (100.0gmL−1) were
removed, neutralized with 0.01M HCl and diluted in buffer num-
ber 1 pH 6.0 to achieve theoretical concentrations of 0.5, 1.5 and
4.5gmL−1.
2.8.4.3. Oxidative degradation. Sample solutions were prepared in
a 30% H2O2 solution and stored at room temperature for 20h. After
that, aliquots of these solutions (100.0gmL−1)were removed and
diluted in buffer number 1 pH 6.0 to achieve theoretical concentra-
tions of 0.5, 1.5 and 4.5gmL−1.
2.8.4.4. Thermal degradation. Methanolic sample solutions were
maintained at 60 ◦C in a dry air oven for 64h. After that, aliquots
of these solutions (100.0gmL−1) were removed and diluted in
buffer number 1 pH 6.0 to achieve theoretical concentrations of
0.5, 1.5 and 4.5gmL−1.
2.8.4.5. Photodegradation. Methanolic sample solutions
(100.0gmL−1) were exposed to UVA radiation (352nm) for
4min. The stress degradation study was performed exposing the
solution in quartz cells in the photodegradation chamber, where
the samples were positioned horizontally to provide maximum
area of exposure to the light source. After that, these solutions
were removed and diluted in buffer number 1 pH 6.0 to achieve
theoretical concentrations of 0.5, 1.5 and 4.5gmL−1. Control
samples protected from light with aluminum foil were also placed
and exposed concurrently in the light chamber.
2.8.4.6. Synthetic impurity. 10.0mg of 1-cyclopropyl-6-ﬂuoro-7-
chloride-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
was accurately weighed and dissolved in a 100mL volumetric
ﬂask with methanol to generate a concentration of 100gmL−1.
Aliquots of this solution were diluted in buffer number 1 pH 6.0 to
provide concentrations of 0.5, 1.5, and 4.5gmL−1.
2.8.4.7. Excipients. The amount of formulation excipients con-
tained in 10.0mg GFM tablets was accurately weighed and
dissolved in a 100mL volumetric ﬂask with methanol. The same
aliquots used to prepare the sample solutions were withdrawn and
diluted in buffer number 1 pH 6.0.
2.8.5. Robustness
Determined by analyzing the sample solution under the follow-
ing conditions: ±0.2% variation in the inoculum concentration and
±0.2 unit variation in the pH value.
2.8.6. Stability of GFM RS and sample solutions
Determined using the HPLC method previously developed and
validated in our laboratory. The solutions were analyzed for 18h
under the chromatographic conditions described in Section 2.8.8.
2.8.7. Cytotoxicity assay
GFM RS and the synthetic impurity solutions were prepared in
aqueous solution (1.0mgmL−1) and diluted in RPMI 1640 medium
nta 83 (2011) 1774–1779 1777
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is the diameter of the inhibition zone. The correlation coefﬁcient
(r=0.9966) was highly signiﬁcant for the method (Fig. 3).
Antibiotic assays must be designed in such a way that they
allow the mathematical model’s validity to be examined based on
a potency equation. According to the Brazilian and European Phar-C.S. Paim et al. / Tala
mmediately before use to the concentrations of 10.0, 30.0, and
0.0gmL−1. The photodegraded solutionwas prepared by expos-
ng GFM RS in aqueous solution (1.0mgmL−1) to UVA radiation
352nm) for 30min. After the period of exposure, the solution was
iluted under the same conditions described above.
Human mononuclear cells were separated from the periph-
ral blood of three healthy donors. Heparinized venous blood was
iluted 4:3 with Hank’s balanced salt solution. The mononuclear
ells were isolated by centrifugation on a Ficoll-Paque® gradient
entrifuge and washed twice in Hank’s solution. Viable cells were
ounted by trypan blue exclusion in a Neubauer chamber. The
ononuclear cellswerewashed and resuspended in RPMI to a con-
entration of 106 viable cells in 1.0mL. These cell suspensions were
ispensed in 96-well plates (100L in each well), and the samples
ere immediately added (100L ineachwell) to those cells. In each
ell the ﬁnal analyzed concentration of each sample was 10.0, 30.0
nd 90.0gmL−1, in triplicate. Controls with mononuclear cells
ere included. Cells were cultivated in a humidiﬁed 5% CO2 incu-
ator at 37 ◦C for 24 and 72h. Cell viability was determined by ﬂow
ytometry after addition of propidium iodide. Analyses were con-
ucted on a FACSCalibur® cytometer equipped with 488nm argon
aser using the CellQuest® Software. The WinMDI 2.8 software was
sed to obtain the ﬁnal results.
.8.8. HPLC method
The GFM concentration analysis was performed on an Agilent®
iquid chromatographwith aRP-18 column. Themobile phase com-
rised a mixture of 0.3% triethylamine solution (pH adjusted to 3.0
ith 10% phosphoric acid) and acetonitrile (80:20, v/v) at a ﬂow
ate of 1.0mLmin−1 and isocratic elution. The injection volumewas
0L for both reference substance and drug product solutions and
he run timewas 8min. The temperaturewas set at 25 ◦C in the col-
mn oven. GFM was determined by UV detection at 272nm using
hotodiode-array.
.8.9. Comparison of methods
In order to compare the bioassay developed against a sec-
nd well-characterized procedure (the previously validated HPLC
ethod), the precision results of both methods were statistically
nalyzed using the Student’s statistical t test, which indicates
hether there is a signiﬁcant difference between two methods at
5% signiﬁcance level.
. Results and discussion
.1. Analytical method
The potency of an antibiotic may be demonstrated under suit-
ble conditions by comparing the growth inhibition of sensitive
icroorganisms produced by known concentrations of the antibi-
tic to be examined and a RS [17]. In this experimental study a 3×3
esign, using three dose levels for standard and sample solutions,
as used following the procedure described in the Brazilian and
uropean Pharmacopoeias [16,18]. The calculation procedure nor-
ally assumesadirect relationshipbetween theobserveddiameter
f the inhibition zone and the logarithm of the applied dose.
Biological methods are advantageous because the measured
arameters and the therapeutic properties of thedrug are the same.
mpurities and related substances do not interfere,maintaining the
recision of the analyticalmethod [21]. Therefore,microbial or bio-
ogical assays remain, in general, the standard for dispelling doubts
bout the potential loss of activity [17].
The experimental conditions of the proposed method were
ested and adjusted to accurately determine the performance of
he assay. The in vitro activity of GFM was tested against S. epider-
idis ATCC 12228 and Micrococcus luteus ATCC 9341. The strainFig. 2. Agar diffusion assay (cylinder–plate method) using a strain of S. epidermidis
ATCC 12228. GFM reference substance concentrations: 0.5 (S1), 1.5 (S2), and 4.5
(S3)gmL−1. Sample concentrations: 0.5 (T1), 1.5 (T2), and 4.5 (T3)gmL−1.
of S. epidermidis ATCC 12228 was shown to be an appropriate
test microorganism because of its sensitivity to GFM and ability
to form sharply deﬁned inhibition growth zones, allowing accu-
ratemeasurements (Fig. 2). For handlingmicroorganisms, all safety
procedures (wearing masks, gloves and goggles) were adopted.
All assays were performed in a laminar air ﬂow cabinet, and the
infected material was decontaminated before being discarded.
The stability analysis of GFM RS and sample solutions, both
quantiﬁedusing theHPLCmethod, demonstrated that the solutions
were stable during the period of analysis (18h) as the GFM area
remained constant and the chromatograms did not show degrada-
tion peaks.
3.2. Linearity
The calculation procedure usually assumes a direct relation-
ship between the observed zone diameter and the logarithm of
the applied dose. The corresponding mean zone diameters for
reference solutions were: 19.29mm (RSD=4.74%) for the lower
dose (0.5gmL−1), 21.33mm (RSD=3.32%) for the medium dose
(1.5gmL−1), and 24.36mm (RSD=1.85%) for the higher dose
(4.5gmL−1). The calibration curves for GFM were constructed
by plotting the log concentration (gmL−1) versus the zone
diameter (mm) and showed good linearity between the 0.5 and
4.5gmL−1 range. The representative linear equation for GFM
was y=7.409x+19.689, where x is the log concentration and yFig. 3. GFM calibration curve obtained by the microbiological cylinder–plate assay.
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Table 1
Intra-assay and inter-assay precision data for the GFM bioassay in the pharmaceu-
tical formulation.
Sample Day Potency
founda (%)
RSD (%)
1
1
98.37
1.022 99.26
3 100.39
4
2
97.96
0.305 98.04
6 98.50
7
3
97.85
0.488 97.70
9 98.58
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Table 2
Robustness results and Student’s statistical t test for the bioassay of GFM pharma-
ceutical formulation.
Parameters Potency
founda (%)
Stat t t-Theoretical
(˛=0.05)
Inoculum concentration (1.8%) 97.49 0.14
2.26
99.45
Inoculum concentration (2.2%) 98.12 0.55
98.22
Buffer solution pH (5.8) 100.45 0.50
97.42Inter-assay 98.52 0.86
a Mean of eight determinations.
acopoeias [16,18], if a parallel-line model is chosen, the two log
ose–response lines of the preparations to be examined as well as
he reference preparation must be parallel and must be linear over
he range of doses used in the calculation. These conditions were
eriﬁed by validity tests for a given probability bymeans of ANOVA,
o deviation from parallelism and linearity was found (p>0.05),
nd the regression was highly signiﬁcant (p<0.05).
.3. Precision and accuracy
The precision and accuracy of the assay were also demon-
trated. The experimental values obtained for the GFM determined
n samples are presented in Table 1. The precision of the assay was
etermined by repeatability (intra-assay) and intermediate preci-
ion (inter-assay), and the results were expressed as the RSD of
he measurement series. The repeatability (intraday precision) was
tudiedby thedeterminationof samples in threeassays, at the same
oncentration and under the same experimental conditions. The
esults obtained showed RSD values lower than 2.0%, indicating
ood intra-assay precision. Inter-assay variability was calculated
rom assays on 3 different days and had an RSD of 0.86%.
Accuracy was evaluated by simultaneous determination of the
nalyte in solutionspreparedvia the standardadditionmethod. The
ecovery rates (99.98, 99.36 and 102.65%) were close to the actual
ample values.
.4. Speciﬁcity
Alsante et al. [22] suggested a target degradation of 5–20% for
stablishing the stability-indicating nature of an assay method,
ince intermediate degradation products should not interfere in
ny stage of drug analysis. Hence, the same degradation conditions
sed to validate the stability-indicating HPLC method, previously
alidated in our laboratory, were employed in the microbiological
ssay.
During the speciﬁcity analysis using the formulation excipients
nd diluents, no inhibition zonewas formedunder the study condi-
ions, revealing the absence of interference from these substances.
oreover, growth inhibition zone diameters did not increasewhen
xcipients were added to the GFM RS.
Degradation under acidic conditions (0.1M HCl for 1h) led
he GFM sample solution to be unstable during the validation of
he HPLC method. Under those conditions, the drug concentration
ecreased by 6.52%. Such instability was also detected during the
icrobiological assay, when drug activity decreased about 9.99% in
.1M HCl for 1h.
During the initial forced degradation experiments analyzed by
PLC, fast degradation was observed in a 0.1M NaOH solution atBuffer solution pH (6.2) 96.54 1.96
97.87
a Mean of eight determinations.
room temperature. As a result, the drug was exposed to a 0.01M
NaOHsolution for 3h to achieve a lower degradation rate. The same
conditions were applied to the microbiological study, and results
showed5.06% drug degradation in the pharmaceutical preparation,
similar to the results by the HPLC method (6.84%).
Under photolytic conditions (UVA radiation), fast GFM degra-
dation was found in a methanolic solution. Results showed 13.49%
degradation when the drug solution was exposed to UVA radia-
tion for 4minandanalyzedbymicrobiological assay. Similar results
were obtained by the HPLC method (14.27%).
The GFM sample solution submitted to thermal degradation
conditions (60 ◦C for 64h) showed degradation of 10.14%. Similar
results were obtained with the HPLC method (9.89%).
Theoxidative stress conditions couldnot be evaluateddue to the
bactericide activity of the 30% hydrogen peroxide solution used as
the oxidative agent.
Results also showed that the GFM synthetic impurity had no
activity against S. epidermidis in the applied conditions, as grown
inhibition zonediameters didnot changewhen the synthetic impu-
rity was added to the GFM sample solution.
Considering all the stress conditions used to develop and val-
idate both methods, it is possible to conclude that the drug
is unstable under photolytic, thermal, acid and alkaline condi-
tions. Moreover, this study suggests that the degradation products
formed and the GFM synthetic impurity, at the concentrations
applied, did not show activity against S. epidermidis, demonstrating
the selectivity of the microbiological assay used to determine GFM
in coated tablets.
3.5. Robustness
Table 2 shows the robustness results of the analytical method.
The values obtained during the assays were statistically compared
against the precision results of the bioassay method (˛=0.05). The
quantiﬁcation of GFM in coated tablets using the bioassay method
can be considered robust, because none of the factors under study
had a signiﬁcant effect on the determination of drug potency.
3.6. Cytotoxicity assay
A cytotoxicity assay with mononuclear cells was performed to
evaluate the effect of the degraded structures in relation to the
intact molecule, to foresee possible undesirable effects resulting
from unstable samples. Non-signiﬁcant differences (p>0.05) were
obtained, indicating that the degraded samples did not show an
increase in cytotoxicity when exposed to the assayed cell culture
after 24h of exposure. In contrast, after 72h of incubation, the GFM
RS and photodegraded GFM RS showed cytotoxic effects with a
reduction in cell viability (Table 3). This effect was not observed
for the synthetic impurity in the concentrations under study.
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Table 3
Results of cell viability obtained by in vitro cytotoxic assay with mononuclear cells for GFM RS, photodegraded GFM RS and synthetic impurity.
Concentration (gmL−1) GFM RS Photodegraded GFM RS Synthetic impurity
Cell viability (%)a ± SD (incubation time 72h)
10 99.88 ± 0.21 100.00 ± 0.0 98.81 ± 2.06
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90 52.87 ± 6.44
a Mean of three analyses.
The results of the statistical analysis of cell viability showed that
here is no signiﬁcant difference between the cytotoxicity of GFM
S and that of the photodegraded GFM at 90gmL−1 after 72h
f incubation (ANOVA, ˛=0.05). Such results corroborate other
tudies that investigated the potential cytotoxicity of quinolones
23,24]. The synthetic impurity showed little cytotoxicity under the
tudy conditions.
.7. Comparison of methods
The quantiﬁcation of antibiotic components by chemical meth-
ds such as HPLC and UV spectrophotometry, although precise,
annot provide a true indication of biological activity. Attempts
o correlate the results obtained from the antibiotic bioassay with
hose from chemical methods have turned out to be disappoint-
ng. Therefore, bioassays continue to play an essential role in the
anufacturing and quality control of antibiotic medicines and still
emand considerable skills and expertise to assure success [25]. For
ethod comparison purposes, GFM samples in coated tablets were
eterminedby themicrobiological assayandHPLCmethods. For the
icrobiological assay method, the mean potency found (±RSD%)
as 98.52%±0.86% and for the HPLC method, 99.57±1.57%. These
esults were statistically analyzed using Student’s t test and indi-
ated that therewas no signiﬁcant difference between themethods
t ˛=0.05 (tcalculated 1.87< ttheoretical 2.06). Therefore, the meth-
ds developed and validated provided similar results for GFM
uantitation in tablets. Moreover, potency results were within the
harmacopeial potency limits of 90–110% applied to antimicrobial
harmaceutical preparations [17].
. Conclusions
For routine quality control ofmedicines, it is essential to employ
ell-characterized, fully validated analytical methods to obtain
eliable results that can be satisfactorily interpreted. The results
btained in this study show that the proposed microbiological
ethod for the determination of GFM in a pharmaceutical dosage
orm is accurate, speciﬁc, robust, and possesses excellent linearity
nd precision characteristics. Moreover, there is no statistical dif-
erence between the microbiological assay and the HPLC method
developed and validated in a previous study) for drug quantiﬁca-
ion; therefore, these can be interchangeable. The bioassay is less
xpensive and very appropriate when an HPLC system is not avail-
ble for antibiotic potency determination. Therefore, the proposed
ioassay is a useful methodology for quality control and stability
[
[
[7.80 ± 5.32 98.44 ± 2.69
9.11 ± 4.69 96.77 ± 5.15
studies of GFM inpharmaceutical products. The in vitro cytotoxicity
assaywithmononuclear cells demonstrated that both the photode-
graded GFM RS and the GFM RS have similar cytotoxicity under the
study conditions.
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